USFDA Approves Advair Generic: Boost for Aurobindo, Blow for Cipla

• USFDA granted final approval for a generic version of Advair Diskus to Respirent Pharmaceuticals and Lannett.
• Advair is a crucial respiratory drug for asthma and chronic obstructive pulmonary disease.
• Aurobindo Pharma's acquisition of Lannett, expected to close soon, makes this approval a positive for Aurobindo.
• The approval intensifies competition, negatively impacting Cipla, which has been awaiting approval for its own Advair generic since 2020.
• Analysts predict increased market share risk and reduced peak sales for Cipla's Advair inhaler due to new competition.

Why It Matters: USFDA's Advair generic approval benefits Aurobindo Pharma via Lannett acquisition, but increases competition for Cipla.